West Pharmaceutical Services Quarterly Cash Flow Statement
NYSE: WSTHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
West Pharmaceutical Services free cash flow
In the quarter ended Jun 30, 2026, West Pharmaceutical Services generated $124.0 million of operating cash flow and spent $43.2 million on capital expenditures. That left free cash flow of $80.8 million, a free-cash-flow margin of 9.3% of revenue. Free cash flow was down 20.7% from the prior year's $101.9 million.
West Pharmaceutical Services returned $172.4 million to shareholders: $15.7 million in dividends and $156.7 million in share repurchases, equal to 213% of free cash flow. Free cash flow covered dividend payments 5.1 times.
Summary generated from market data by MetaCap's automated system. Methodology
West Pharmaceutical Services cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 154.00M | 138.80M | 132.10M | 140.00M | 131.80M | 89.80M | 130.10M | 136.00M | 111.30M | 115.30M | 137.00M | 161.30M |
| Net Income growth (YoY) | +16.84% | +54.57% | +1.54% | +2.94% | +18.42% | -22.12% | -5.04% | -15.69% | -28.24% | -17.64% | +33.01% | +33.75% |
| Depreciation & Amortization | 46.20M | 45.20M | 47.00M | 43.00M | 41.40M | 40.00M | 40.70M | 40.20M | 38.90M | 35.60M | 34.60M | 34.80M |
| Stock-Based Compensation | 10.90M | 6.60M | 6.70M | 8.40M | 7.40M | 1.30M | 4.30M | 5.10M | 4.30M | 5.00M | 1.40M | 5.90M |
| Change in Working Capital | -86.00M | -102.90M | 6.40M | 2.10M | -4.10M | 100.00K | -600.00K | -100.00K | 14.10M | -34.60M | — | 24.80M |
| Operating Cash Flow | 124.00M | 89.90M | 251.10M | 197.20M | 177.10M | 129.40M | 190.10M | 180.10M | 165.00M | 118.20M | 239.10M | 230.10M |
| Capital Expenditures | -43.20M | -42.70M | -76.10M | -63.30M | -75.20M | -71.30M | -104.90M | -81.30M | -100.20M | -90.60M | -108.70M | -95.80M |
| Investing Cash Flow | -43.20M | -42.70M | -76.10M | -63.30M | -75.20M | -71.30M | -104.80M | -82.10M | -101.20M | -90.60M | -108.80M | -95.70M |
| Dividends Paid | -15.70M | -15.80M | -15.80M | -15.10M | -15.10M | -15.20M | -15.30M | -14.50M | -14.60M | -14.70M | -14.80M | -14.00M |
| Share Repurchases | -156.70M | -297.60M | 0 | 0 | -500.00K | -133.50M | -54.40M | -52.40M | -187.10M | -267.00M | -177.00M | -27.80M |
| Debt Issued | — | — | 0 | 0 | — | — | 0 | 129.70M | — | — | — | 0 |
| Debt Repaid | — | — | 0 | 0 | 0 | 0 | 0 | -132.90M | -35.50M | -600.00K | — | — |
| Financing Cash Flow | -164.80M | -308.70M | -11.70M | -11.50M | -14.90M | -147.00M | -68.90M | -64.40M | -218.30M | -271.00M | -189.50M | -22.30M |
| Net Change in Cash | -85.60M | -269.90M | 162.80M | 118.80M | 105.50M | -80.40M | -6.30M | 44.70M | -155.60M | -252.10M | -44.70M | 102.30M |
| Free Cash Flow | 80.80M | 47.20M | 175.00M | 133.90M | 101.90M | 58.10M | 85.20M | 98.80M | 64.80M | 27.60M | 130.40M | 134.30M |
This table shows 12 quarterly periods of West Pharmaceutical Services's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow WST's reporting calendar. What is a cash flow statement?